Handbook of Experimental Pharmacology, Continuation of Handbuch der experimentellen Pharmakologie,, 71.
1 Interferons and Their Applications: Past, Present, and Future --; 2 Assay of Interferons. With 1 Figure --; 3 Evolution of Interferon Genes. With 11 Figures --; 4 Comparative Analysis of Interferon Structural Genes With 2 Figures --; 5 Comparative Structures of Mammalian Interferons With 9 Figures --; 6 Regulatory Control of Interferon Synthesis and Action With 6 Figures --; 7 Application of Recombinant DNA Technology to Expression of Human Interferon Genes --; 8 The Molecular Mediators of Interferon Action With 2 Figures --; 9 The Cellular Effects of Interferon --; 10 Interferon Induction by Viruses. With 8 Figures --; 11 Interferon Induction by Nucleic Acids: Structure-Activity Relationships With 4 Figures --; 12 Production and Characterization of Human Leukocyte Interferon With 2 Figures --; 13 Lymphoblastoid Interferon: Production and Characterization --; 14 Fibroblast Interferons: Production and Characterization. --; 15 Immune Interferon. With 9 Figures --; 16 Comparative Biologic Activities of Human Interferons --; 17 Manufacture and Safety of Interferons in Clinical Research --; 18 Nonpolynucleotide Inducers of Interferon. With 4 Figures --; 19 Agents Which Modulate the Activity of Interferon --; 20 Effects of Interferon and Its Inducers on Leukocytes and Their Immunologic Functions. --; 21 Clinical Use of Interferons: Localized Application in Viral Diseases With 3 Figures --; 22 Clinical Use of Interferons: Systemic Administration in Viral Diseases --; 23 Clinical Use of Interferons: Central Nervous System Disorders With 5 Figures --; 24 Clinical Investigation of Interferons: Status Summary and Prospects for the Future --; 25 Utilization of Stabilized Forms of Polynucleotides With 9 Figures --; 26 Therapeutic Applications of Double-Stranded RNAs With 3 Figures --; 27 Monoclonal Antibodies to Interferons.
Today, the basic mood of researchers and clinical investigators, both at the center and on the periphery of interferon studies, is optimistic regarding the future of interferons as therapeutic substances. Many also feel these polypeptides will prove invaluable probes in unraveling certain fundamental biochemical processes which control the life cycle and developmental pattern of many human cells. In contrast, only a year or two ago, this optimism had given way to an attitude almost of disenchantment as public and scientific expectations were raised steeply, then rapidly waned, as it turns out, prematurely. Both the mUltiple actions of interferons (a virtual cascade of biochemical reactions may be induced, as documented herein) and the high visibility of interferon research provided by the millions of dollars invested both by national health agencies and by multinational pharmaceutical companies, contributed to an upsweep in public attention to drug development probably unprecedented in this century. Virtually every oncologist, it would seem, was plagued by requests for the experimental agent, although they already had therapies of more proven value. As recently as 1980, even though interferon had achieved success against certain cancers and certain viral diseases, the variability in clinical results was seemingly ever present and little evidence emerged to suggest interferons could cure advanced diseases. Why then the resurgence of an optimistic mood? There are almost always many elements which contribute to happiness, and this is certainly true of the broad frontier of interferon and its place in biochemical research and treatment.